RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Consensus Rating of "Hold" by Brokerages

Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) have been assigned a consensus recommendation of "Hold" from the six ratings firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $3.00.

Several brokerages recently issued reports on RAPT. UBS Group reduced their price objective on shares of RAPT Therapeutics from $2.00 to $1.00 and set a "neutral" rating on the stock in a report on Thursday, May 22nd. Wall Street Zen raised RAPT Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Finally, HC Wainwright raised RAPT Therapeutics to a "strong-buy" rating and set a $6.00 price target for the company in a report on Thursday, May 22nd.

Institutional Investors Weigh In On RAPT Therapeutics

Hedge funds have recently modified their holdings of the stock. TCG Crossover Management LLC purchased a new stake in RAPT Therapeutics during the 4th quarter worth approximately $19,751,000. Orbimed Advisors LLC bought a new position in RAPT Therapeutics during the 4th quarter worth $20,754,000. Foresite Capital Management VI LLC bought a new position in shares of RAPT Therapeutics in the fourth quarter worth $19,750,000. RTW Investments LP acquired a new stake in shares of RAPT Therapeutics in the fourth quarter valued at $18,587,000. Finally, BVF Inc. IL purchased a new stake in shares of RAPT Therapeutics during the fourth quarter valued at $14,595,000. 99.09% of the stock is currently owned by hedge funds and other institutional investors.

RAPT Therapeutics Price Performance

RAPT traded up $0.15 during trading on Tuesday, reaching $1.17. 953,506 shares of the company's stock were exchanged, compared to its average volume of 1,285,947. RAPT Therapeutics has a 1 year low of $0.71 and a 1 year high of $4.01. The stock has a market capitalization of $154.78 million, a P/E ratio of -0.42 and a beta of -0.04. The company's fifty day simple moving average is $0.92 and its 200-day simple moving average is $1.12.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.23. Equities analysts forecast that RAPT Therapeutics will post -2.14 EPS for the current year.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.